EORTC Presentations at ASCO 2016 in Chicago

The EORTC will present 12 abstracts at the ASCO 2016 Annual Meeting which will be held 3 – 7 June 2016 in Chicago, Illinois. Two abstracts will be presented in Oral Abstract Sessions, nine in General Poster Sessions and one publication.

Oral Abstract Sessions

Title: Interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in 1p/19q-intact anaplastic glioma. An intergroup trial. Authors: Martin J. Van Den Bent, Sara Erridge, Michael A. Vogelbaum, Anna K. Nowak, Marc Sanson, Alba Ariela Brandes, Wolfgang Wick, Paul M. Clement, Jean-Francois Baurain, Warren P. Mason, Helen Wheeler, Olivier L. Chinot, Michael Weller, Vassilis Golfinopoulos, Ken Aldape, Winand N.M. Dinjens, Pieter Wesseling, Thierry Gorlia, Johan M Kros, Brigitta G. Baumert

Title: EORTC 26101 trial phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. Authors: Wolfgang Wick, Alba Ariela Brandes, Thierry Gorlia, Martin Bendszus, Felix Sahm, Walter Taal, Martin J.B. Taphoorn, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M. Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, François Dubois, Martin Klein, Michael Platten, Michael Weller, Vassilis Golfinopoulos, Martin J. Van Den Bent

General Posters Sessions

Title: TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV Squamous Cell Carcinoma of the Head and Neck (HNSCC): a randomized phase II EORTC trial. Authors: Pol M. Specenier, Eva Remenar, J. Buter, Dirk L. Schrijvers, Lisa F. Licitra, Ahmad Awada, Paul M. Clement, Catherine Fortpied, Ravi Karra Gurunath, Jan Baptist Vermorken

Title: Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111. Authors: Jean-Pascal H. Machiels, Jessica Menis, Michela Lia, Catherine Fortpied, Renaud Lhommel, Marc Lemort, Marco Guzzo, Roberto Bianchi, Flavio Crippa, Pasquale Quattrone, Paolo Bossi, Sandra Schmitz, Thierry Duprez, Yassine Lalami, Marie Quiriny, Nicolas de Saint Aubain, Paul M. Clement, Ruxandra Coropciuc, Esther Hauben, Lisa F. Licitra

Title: EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer. “INNOVATION” trial.
Authors: Anna Dorothea Wagner, Yoon-Koo Kang, Jolanda van Dieren, Murielle E. Mauer, Heike I Grabsch, Michela Lia, Ajlan Atasoy, Jae Yong Cho, Markus H. Moehler, Arnaud Roth, Manuel Salto-Tellez, Christoph Schumacher, Nicole C.T. van Grieken, Johanna W. van Sandick, Florian Lordick

Title: EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage Non Small Cell Lung Cancer (NSCLC) after resection and standard adjuvant chemotherapy (PEARLS, NCT02504372).
Authors: Mary E.R. O’Brien, Baktiar Hasan, Urania Dafni, Jessica Menis, Solange Peters, Michele De Waele, Rolf A. Stahel, Paul Van Schil, George Coukos, Sylvie Lantuejoul, Keith M. Kerr, Ignacio Melero, Benjamin Besse, Luis G. Paz-Ares

Title: Disease free survival (DFS) is a surrogate for Overall Survival (OS) in Localized Prostate Cancer (CaP). Authors: Christopher Sweeney, Wanling Xie, Meredith M. Regan, Mari Nakabayashi, Marc E. Buyse, Noel W. Clarke, Laurence Collette, James J. Dignam, Karim Fizazi, Muriel Habibian, Susan Halabi, Philip W. Kantoff, Wendy R. Parulekar, Howard M. Sandler, Oliver Sartor, Howard R. Soule, Matthew Robert Sydes, Bertrand F. Tombal, Scott G. Williams

Title: Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial. Authors: Greg Yothers, Thomas J. George Jr., Carmen Joseph Allegra, Jean-Francois Bosset, Krzysztof Bujko, Laurence Collette, Michael J. O’Connell, Jerome Doyen, Carlos Fernandez-Martos, Jean Francois Seitz, Norman Wolmark

Title: Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients: side study of the EORTC 18961 trial. Authors: Judith Michels, Natalia Becker, Stefan Suciu, Iris Kaiser, Axel Benner, Sandrine Agoussi, Niels Halama, Michael Pawlita, Tim Waterboer, Stefan Eichmüller, Dirk Jäger, Alexander M. Eggermont, Inka Zoernig

Title: Phase II part of EORTC study 26101: the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. Authors: Wolfgang Wick, Roger Stupp, Thierry Gorlia, Martin Bendszus, Felix Sahm, Jacoline E Bromberg, Alba Ariela Brandes, Maaike J Vos, Julien Domont, Ahmed Idbaih, Jean-Sebastien Frenel, Paul M. Clement, Michel Fabbro, Emilie Le Rhun, François Dubois, Davide Musmeci, Michael Platten, Vassilis Golfinopoulos, Martin J. Van Den Bent

Title: A review of the quality of statistical methods employed for analyzing quality of life data in cancer RCTs. Authors: Andrew Bottomley, Corneel Coens, Jammbe Musoro, Francesca Martinelli, Efstathios Zikos, Irina Ghislain, Jean-Francois Hamel

Publication

Title: Update of the EORTC questionnaire for assessing quality of life in patients with lung cancer? introducing the new EORTC QLQ-LC29. Author: Michael Koller